Rheumatology-TP 1..2
Total Page:16
File Type:pdf, Size:1020Kb
Rheumatology 2016 The British Society for Rheumatology, British Health Professionals in Rheumatology and the British Society for Paediatric and Adolescent Rheumatology Annual Meeting 26 – 28 April 2016 Scottish Exhibition þ Conference Centre, Glasgow, UK The abstracts are freely available online to all visitors to the Rheumatology website (http://www.rheumatology.oxfordjournals.org). RheumatologyDOI is incorrect10.1093/rheumatology/ker000ker000ContentsRheumatologyContents- Contents2016000000002016Volume 51 Supplement 1 April 2016 Volume 55 Supplement 1 April 2016 CONTENTS Rheumatology 2016 Abstracts INVITED SPEAKER ABSTRACTS (TUESDAY 26 APRIL 2016) I01–I03 Medico-legal issues in rheumatology i1 i04–i06 What patients want from their rheumatology service i1 i07–i09 Rheumatology in the world of social media i2 I10–I12 Pulmonary hypertension for rheumatologists i2 I13–I15 The three S’s in rheumatology i3 I16–I18 The BSRBR-RA at 15 years: lessons learned and future challenges i3 I19–I21 Men with rheumatoid arthritis i4 I22–I24 Make life easier for yourself: get patients inputting the data! i4 I25–I27 Why do we need a stratified medicine approach in rheumatic diseases? i5 I28–I30 Occupational rheumatology for the uninitiated: work and upper limb disorders i5 I31–I33 Management of vascular manifestations of the skin, kidneys and GI tract in systemic i6 sclerosis I34–I35 Dissemination and communication throughout your doctorate i7 I36–I37 Getting started with your audit/research project i7 I38 Jewels in the Crown i7 I39–I40 Michael Mason and Garrod Prize Winners i7 I41–I43 Top Scoring Abstracts (presented in Jewels in the Crown) i8 I44 Heberden Round i9 INVITED SPEAKER ABSTRACTS (WEDNESDAY 27 APRIL 2016) I45–I47 BRiTs: How to survive as a consultant: all the things you need to know i10 I48–I50 BSI: How targeted therapies reveal the immunology of autoimmune rhematic disease i10 I51-I53 BSI: Imaging immunology and inflammation in action i11 I54–I56 BSI: The role of RNA species and RNA binding proteins in the joint i11 I57–I59 Essentials: Disease management i12 I60–I62 Essentials: Symptom management i12 I63–I64 Essentials: Experts in the field i13 I65–I68 Engaging with South Asian community in rheumatology care i13 I69–I71 BSR clinical guidelines i14 I72–I76 Assessing disease activity and damage in vasculitis: an interactive practical session i15 I77–I79 Common musculoskeletal foot problems in primary care i15 I80–I82 Foot problems in inflammatory arthritis i16 I83–I85 Group clinics in musculoskeletal disease: better together i16 I86–I88 Dermatological manifestations in rheumatic disease: all you need to know i17 I89–I91 Supporting self-management for musculoskeletal health i18 I92–I94 Treating early rheumatoid arthritis to target: practice outside the UK i18 I95–I97 Disease modification in osteoarthritis i19 I98 Heberden Oration i19 www.rheumatology.oxfordjournals.org INVITED SPEAKER ABSTRACTS (THURSDAY 28 APRIL 2016) I99–I100 BRiTs 1: The lung in rheumatology i21 I101–I103 BRiTs 2: Radiology for rheumatologists i21 I104–I106 Management of septic arthritis in the 21st century i21 I107–I110 How to manage rheumatic diseases in pregnancy? i22 I111–I113 Psoriatic arthritis: before and after tumor necrosis factor inhibitors i22 I114–I117 Sjo¨ gren’s: welcome to the biologic era! i23 I118–I120 How to cope with statistics in a research paper i23 I121–I123 Rehabilitation in rheumatology: for young and old i24 I124–I126 Pain 1: State of the art: how to assess and manage low back pain i24 I127–I129 Pain 2: State of the art: management of persistent pain i25 I130–I131 Staying physically active with rheumatoid arthritis i26 I132 Droitwich Medical Trust Lecture i26 I133–I135 Adult inflammatory arthritis studies: the importance of longitudinal data collection i26 I136–I138 Fibromyalgia: preventing onset and improving outcome i27 I139–I141 What’s new in the antiphospholipid syndrome? i28 I142–I145 Unravelling knots of silk: Understanding Behc¸ et’s disease i29 I146–I149 Let’s keep axial spondyloarthropathy patients in work, engaged with physical activity and i29 self-managing their disease: an interdisciplinary approach I150–I151 BSR research committee launch party i30 I152–I153 Update on basic science and clinical aspects of systemic lupus erythematosus i30 I154–I156 Gout in the 21st Century i30 I157–I159 Adolescent and young adult rheumatology i31 I160–I162 Getting the most out of patient and public engagement i31 ORAL PRESENTATION OF ABSTRACTS (TUESDAY 26 APRIL 2016) O01–O06 Seronegative and spondyloarthopathies oral abstracts i33 O07–O12 Rheumatoid and vasculitis oral abstracts i36 ORAL PRESENTATION OF ABSTRACTS (WEDNESDAY 27 APRIL 2016) O13–O18 Osteoarthritis and osteoporosis oral abstracts i40 O19–O24 BHPR oral abstracts i43 O25–O30 Connective tissue diseases and muscle disorders oral abstracts i46 O31–O36 Primary care oral abstracts i50 ORAL PRESENTATION OF ABSTRACTS (THURSDAY 28 APRIL 2016) O37–O42 Basic science oral abstracts i53 O43–O48 Paediatric and adolescent oral abstracts i56 O49–O54 Rheumatoid arthritis oral abstracts i59 POSTER VIEWING I (TUESDAY 26 APRIL 2016) 001–027 Case reports i63 028–036 Epidemiology i73 037–052 Primary care i76 053–056 Miscellaneous rheumatic diseases i82 057–059 Rheumatoid arthritis: clinical features i84 060–068 Rheumatoid arthritis: co-morbidities i85 069–072 Rheumatoid arthritis: pathogenesis i89 073–104 Rheumatoid arthritis: treatment i90 POSTER VIEWING II (WEDNESDAY 27 APRIL 2016) 105–115 BHPR Research: qualitative i106 116–126 BHPR Research: quantitative i110 127–147 BHPR: Audit and clinical evaluation i114 148–172 Health services research, economics and outcomes research i121 173–176 Muscle disorders i132 177–180 Orthopaedics and rehabilitation i134 181–185 Osteoarthritis: clinical features i135 186 Osteoarthritis: treatment i137 187–188 Osteoporosis and metabolic bone disease i137 189–202 Spondyloarthropathies (including psoriatic arthritis) i138 www.rheumatology.oxfordjournals.org POSTER VIEWING III (THURSDAY 28 APRIL 2016) 203–207 Basic Science i145 208–210 Cytokines and inflammation i146 211–217 Education i147 218–220 Genetics i150 221–230 Imaging i151 231–238 Paediatric and adolescent rheumatology i155 239–244 Pain i158 245–257 Scleroderma and related disorders i160 258–270 Systemic lupus erythematosus and antiphospholipid syndrome i165 271–284 Vasculitis i171 285–290 Sjo¨ gren’s syndrome and other connective tissue disorders i177 291–294 Soft tissue and regional musculoskeletal disease, fibromyalgia i180 E-POSTERS E01–E07 BHPR: Audit and clinical evaluation i182 E08 BHPR research: quantitative i182 E09–E25 Case reports i182 E26–E28 Epidemiology i184 E29 Genetics i184 E30–E36 Health services research, economics and outcomes research i184 E37–E38 Metabolic and crystal arthropathies i185 E39–E42 Miscellaneous rheumatic diseases i185 E43 Muscle disorders i185 E44 Orthopaedics and rehabilitation i185 E45 Osteoarthritis: treatment i185 E46–E48 Osteoporosis and metabolic bone disease i185 E49 Paediatric and adolescent rheumatology i186 E50 Pain i186 E51–E53 Rheumatoid arthritis: co-morbidities i186 E54–E66 Rheumatoid arthritis: treatment i186 E67 Scleroderma and related disorders i187 E68 Sjo¨ gren’s syndrome and other connective tissue disorders i187 E69–E70 Systemic lupus erythematosus and antiphospholipid syndrome i187 E71 Soft tissue and regional musculoskeletal disease, fibromyalgia i188 E72–E76 Spondyloarthropathies (including psoriatic arthritis) i188 E77 Vasculitis i188 ABSTRACT REVIEWERS i189 Effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the organizers for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, we recommend that independent verification of diagnoses and drug doses should be made. www.rheumatology.oxfordjournals.org i1 Tuesday 26 April 2016 INVITED SPEAKER ABSTRACTS MEDICO-LEGAL ISSUES IN RHEUMATOLOGY WHAT PATIENTS WANT FROM THEIR RHEUMATOLOGY SERVICE I01 CONSENT AND CANDOUR: A MEDICO-LEGAL VIEW Sarah Devaney Healthcare Ethics and Law, University of Manchester, Manchester, I04 FOOT HEALTH EDUCATION FOR PEOPLE WITH UK RHEUMATOID ARTHRITIS: A SURVEY OF PATIENTS’ PERCEIVED NEEDS AND EXPERIENCES In his 2013 report into the Mid-Staffordshire scandal, Robert Francis QC observed that a culture of caring in health care provision requires Andrea Graham ‘a displacement of a culture of fear with a culture of openness, honesty Directorate of Prosthetics, Orthotics and Podiatry, University of and transparency, where the only fear is the failure to uphold the Salford, Salford, UK fundamental standards and the caring culture’. The issue of the provision of information to patients, either in advance of treatment or Objective: Up to 90% of people with RA experience foot problems when something has gone wrong in their care, is a key element of such leading to reduced function, mobility, quality of life and social a culture. Two important legal developments in this area will be participation as well as impacts on body image, but these can be considered in this presentation. First, the 2015 Supreme Court case of improved with general foot care, orthoses, footwear and patient Montgomery v Lanarkshire confirmed informed consent as a key legal education. Patient foot health education is lacking, hence the aim of concept